---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000073"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:33:30.178387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024

## Summary
- Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.
- SCA patients showed 50-70% slower disease progression vs untreated controls, translating to 1.5-2.2 years delay.
- Odds ratio for 2+ point f-SARA worsening at 3 years was 4.1 (95% CI: 2.1, 8.1; p<0.0001) favoring troriluzole.
- Biohaven to submit NDA to FDA in Q4 2024; eligible for priority review given orphan/fast-track designations.
- Company plans US commercialization in 2025 if approved; no FDA-approved treatments currently exist for SCA.

## SEC filing metadata
- accession: 0001935979-24-000073
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000073/0001935979-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000073/bhvn-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000073
- JSON: https://secwatch.observer/filing/0001935979-24-000073.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.